Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO Medicovestor secures 3 USPTO patents, advancing its innovative ADC platform and unique antibodies for enhanced cancer treatment and autoimmune potential.

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.